Psoriasishttps://en.wikipedia.org/wiki/Psoriasis
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa. relevance score : -100.0%
References Psoriasis 28846344 NIH
Phototherapy 33085287 NIH
Tumor Necrosis Factor Inhibitors 29494032 NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).
Mankhwala osiyanasiyana angathandize kuchepetsa zizindikiro. Mankhwalawa akuphatikizapo steroid creams, kirimu cha vitamini D3, kuwala kwa ultraviolet, ndi mankhwala osokoneza bongo, monga methotrexate. Pafupifupi 75% ya kukhudzidwa kwa khungu kumakhala bwino ndi zonona zokha. Mitundu yosiyanasiyana ya biological immunologic agents ikupangidwa kuti ichiritse psoriasis.
Psoriasis ndi matenda wamba ndipo matendawa amakhudza 2-4% ya anthu. Abambo ndi amai amakhudzidwa ndi ma frequency ofanana. Matendawa amatha kuyamba ali ndi zaka zilizonse, koma amayamba akakula. Psoriatic nyamakazi imakhudza mpaka 30% ya anthu omwe ali ndi psoriasis.
○ Kuchiza - Mankhwala OTC
Kuwala kwadzuwa kungathandize psoriasis chifukwa dzuŵa limapangitsa kusintha kwa immunological kwa odwala psoriasis. Mafuta ochepera a hydrocortisone angathandize kuchiza zilonda zazing'ono za psoriasis.
#OTC steroid ointment
○ Machiritso
Psoriasis ndi matenda aakulu ndipo mankhwala ambiri akuphunziridwa. Biologics ndiwothandiza kwambiri koma okwera mtengo kwambiri.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)